Dermorphin — questions, answered plainly.

Dermorphin is a seven-residue opioid peptide isolated from the skin of South American Phyllomedusa tree frogs in the 1980s. It is a highly selective μ-opioid receptor agonist, reportedly 30–40× more potent than morphine in animal models.

Dermorphin is treated as a controlled substance in many jurisdictions due to its high μ-opioid potency. It is also on the World Anti-Doping Agency prohibited list and has documented illicit use in horse racing. Research access is restricted; clinical / unsupervised use is not endorsed.

Amiche 1988 (Int J Pept Protein Res, PMID 2906053) established that the D-Ala residue at position 2 and the C-terminal amidation are critical for dermorphin's high-affinity μ-opioid receptor binding. These features confer proteolytic stability and selective receptor engagement.

DALDA is a dermorphin-derived peripheral μ-opioid agonist designed to provide analgesia without crossing the blood-brain barrier. Gadepalli 2024 (Neurotherapeutics, PMID 38241153) reported that DALDA was associated with reduced paclitaxel-induced neuropathic pain in rats without central side effects.

The parent dermorphin compound is not approved for human use. Analogue development (DALDA, mixed μ/δ modulators) is the primary direction of contemporary research interest, as covered in the Schiller 2005 AAPS Journal review (PMID 16353933).

Dermorphin and its analogues are controlled / WADA-prohibited substances. Published primary evidence is concentrated in 1980s–1990s pharmacology and contemporary analogue research; the parent compound is not in active clinical development.